Hepatic metastases were established by portal vein injection of luciferase-expressing PDA cells that expressed both KRT19 and TGM2 or PDA cells in which the Krt19 or Tgm2 genes had been CRISPR/Cas9 edited. The gene discussed is KRT19; the disease is Patent ductus arteriosus.